TRPV2 and esophageal squamous cell carcinoma: Preoperative adjuvant chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5FU) is currently used with beneficial effects to treat localized advanced ESCC in Japan.[2,3,10] We previously reported that TRPV2 appeared to play a role in maintaining CSCs, and that tranilast, its inhibitor, may enhance the effects of conventional preoperative adjuvant chemotherapy against ESCC.[7] The present study is being performed to confirm the safety and efficacy of the additional use of tranilast with 5-FU/CDDP and to develop a novel therapeutic strategy for patients with advanced ESCC.